- Home
- NAVI vs AUPH Comparison
NAVI vs AUPH Comparison
Compare NAVI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- AUPH
- Stock Information
- Founded
- NAVI 1973
- AUPH 1993
- Country
- NAVI United States
- AUPH Canada
- Employees
- NAVI N/A
- AUPH N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- AUPH Health Care
- Exchange
- NAVI Nasdaq
- AUPH Nasdaq
- Market Cap
- NAVI 1.4B
- AUPH 1.3B
- IPO Year
- NAVI N/A
- AUPH 1999
- Fundamental
- Price
- NAVI $13.92
- AUPH $8.01
- Analyst Decision
- NAVI Sell
- AUPH Strong Buy
- Analyst Count
- NAVI 7
- AUPH 3
- Target Price
- NAVI $14.07
- AUPH $10.33
- AVG Volume (30 Days)
- NAVI 960.6K
- AUPH 1.4M
- Earning Date
- NAVI 01-29-2025
- AUPH 02-13-2025
- Dividend Yield
- NAVI 4.60%
- AUPH N/A
- EPS Growth
- NAVI N/A
- AUPH N/A
- EPS
- NAVI 0.70
- AUPH N/A
- Revenue
- NAVI $1,036,000,000.00
- AUPH $220,361,000.00
- Revenue This Year
- NAVI N/A
- AUPH $36.97
- Revenue Next Year
- NAVI $7.80
- AUPH $16.43
- P/E Ratio
- NAVI $19.97
- AUPH N/A
- Revenue Growth
- NAVI N/A
- AUPH 38.72
- 52 Week Low
- NAVI $12.73
- AUPH $4.71
- 52 Week High
- NAVI $18.37
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- NAVI 52.14
- AUPH 40.52
- Support Level
- NAVI $12.73
- AUPH $7.60
- Resistance Level
- NAVI $13.66
- AUPH $9.31
- Average True Range (ATR)
- NAVI 0.34
- AUPH 0.32
- MACD
- NAVI 0.13
- AUPH -0.12
- Stochastic Oscillator
- NAVI 88.64
- AUPH 27.45
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.